Related Experiment Video
Updated: May 24, 2025
05:57
Fat Preference: A Novel Model of Eating Behavior in Rats
Published on: June 27, 2014
13.1K
GLP-1 Receptor Agonists in Pediatric and Adolescent Obesity
Margaret A Stefater-Richards1,2, Grace Jhe3,4,5, Yanjia Jason Zhang2,6,7
1Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts.
Pediatrics
|March 3, 2025
Summary
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer effective weight management for adolescents with obesity. Clinicians must consider mental health, nutrition, and health equity for optimal GLP-1RA treatment outcomes.
Area of Science:
- Pediatric Endocrinology
- Pharmacology
- Public Health
Background:
- Childhood obesity in the US is a significant public health issue, driving numerous related diseases.
- Effective interventions require both societal changes and healthcare innovations.
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a recent advancement approved for adolescent obesity treatment.
Purpose of the Study:
- To review pediatric clinician considerations for the effective use of GLP-1RAs in adolescent obesity care.
- To provide an overview of the history and development of obesity pharmacotherapies, including GLP-1RAs.
- To highlight key aspects of comprehensive obesity management, including mental health, nutrition, and health equity.
Main Methods:
- Review of the history of obesity pharmacology and the development of GLP-1RAs.
- Examination of current indications for GLP-1RA use in adolescents.
- Discussion of adverse reactions, mental health integration, nutritional considerations, and health equity issues.
Main Results:
- GLP-1RAs demonstrate effectiveness in weight management and ameliorating obesity-related diseases in adolescents.
- Comprehensive care must address mental health, particularly disordered eating behaviors.
- Nutritional status requires careful monitoring during GLP-1RA therapy.
- Health inequities in obesity risk and treatment access must be addressed to prevent exacerbation.
Conclusions:
- GLP-1RAs represent a valuable tool within a comprehensive pediatric obesity treatment plan.
- Integrating mental health support and nutritional guidance is crucial for successful pharmacotherapy.
- Ensuring equitable access to GLP-1RAs is essential to avoid widening existing health disparities.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
290
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
290
01:06Oral Hypoglycemic Agents: Glinides
129
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
129
01:23Dipeptidyl Peptidase 4 Inhibitors
161
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
161
01:30Regulation of Food Intake
174
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
174
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
151
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
151
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
142
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
142